Inflammatory activity can continue within the vascular wall through the actions of immune cells and inflammatory mediators. These processes contribute to endothelial dysfunction, atherosclerotic plaque progression, and plaque instability. Their persistence helps explain why cardiovascular vulnerability may remain even after an important traditional risk factor, such as low-density lipoprotein cholesterol, has been treated.
Cholesterol-related risk reflects the contribution of lipid levels, whereas residual inflammatory risk reflects ongoing inflammatory activity that may remain after lipid management. The two processes can contribute to cardiovascular disease at the same time. This distinction supports a broader prevention strategy that considers inflammation alongside lipid lowering and other established interventions.
High-sensitivity C-reactive protein, commonly abbreviated as hsCRP, serves as a clinical marker of inflammatory activity relevant to cardiovascular risk. Its measurement can help identify patients whose inflammatory risk may remain clinically important despite standard preventive treatment. In this way, hsCRP supports risk assessment rather than replacing evaluation of traditional cardiovascular factors.
Clinicians can consider persistent inflammatory activity together with traditional cardiovascular risk factors and the effects of standard preventive therapy. A marker such as hsCRP may help identify patients who remain vulnerable to recurrent cardiovascular events. This added perspective can refine risk stratification by recognizing that controlled lipid levels do not necessarily capture all ongoing vascular risk.
It provides a clinical framework for asking whether targeting inflammation adds benefit beyond established prevention. Research can evaluate anti-inflammatory treatments in patients who remain at risk despite standard therapy, using cardiovascular vulnerability and inflammatory markers as relevant considerations. This approach separates the potential contribution of inflammation from the effects already addressed through lipid lowering.
The concept encourages investigation into how persistent vascular inflammation contributes to recurrent cardiovascular events and how best to identify patients affected by it. It also supports studies of strategies that target inflammation alongside lipid lowering and other interventions. Research in this area connects biological mechanisms, clinical markers, risk stratification, and evaluation of new preventive approaches.